|Trade names||Hidrasec, Tiorfan, others|
|Other names||Benzyl 2-[3-(acetylthio)-2-benzylpropanamido]acetate|
|AHFS/Drugs.com||International Drug Names|
|Protein binding||90% (active thiorphan metabolite)|
|Elimination half-life||3 hours|
|Excretion||Urine (81.4%), feces (8%)|
|Chemical and physical data|
|Molar mass||385.47662 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Racecadotril, also known as acetorphan, is an antidiarrheal drug which acts as a peripherally acting enkephalinase inhibitor. Unlike other opioid medications used to treat diarrhea, which reduce intestinal motility, racecadotril has an antisecretory effect — it reduces the secretion of water and electrolytes into the intestine. It is available in France (where it was first introduced in ~1990) and other European countries (including Germany, Italy, the United Kingdom, Spain, Russia and the Czech Republic) as well as most of South America and some South East Asian countries (including China, India and Thailand), but not in the United States. It is sold under the tradename Hidrasec, among others. Thiorphan is the active metabolite of racecadotril, which exerts the bulk of its inhibitory actions on enkephalinase.
Racecadotril can be used for treatment of acute diarrhea patients and has better tolerability than loperamide. Several guidelines have recommended racecadotril use in addition to oral rehydration treatment in children with acute diarrhea.
Racecadotril is rapidly absorbed after oral administration and doses of 30 mg, 100 mg and 300 mg reached Cmax within 60 min. Food does not affect bioavailability of racecadotril. Racecadotril is rapidly and effectively metabolized to the active metabolite thiorphan which inhibits enkephalinase enzyme and exhibits anti-secretory effect.
In France it is sold as Tiorfan and in Italy as Tiorfix. In India it is available as Redotril and Enuff.